US FDA GMP Inspection Programs – Pharma GMP

Introduction to US FDA GMP Compliance Framework

digi — Sat, 31 May 2025 23:17:26 +0000

Introduction to US FDA GMP Compliance Framework Overview of the US FDA GMP Compliance Framework for Pharmaceutical Manufacturers The United States Food and Drug Administration (US FDA) plays a pivotal role in ensuring the quality and safety of drugs through its comprehensive Good Manufacturing Practice (GMP) compliance framework. All pharmaceutical products intended for the US...

Understanding 21 CFR Parts 210 and 211 for GMP

digi — Sun, 01 Jun 2025 04:39:34 +0000

Understanding 21 CFR Parts 210 and 211 for GMP A Comprehensive Guide to 21 CFR Parts 210 and 211 for GMP Compliance Compliance with the US FDA’s Good Manufacturing Practice (GMP) regulations is essential for any pharmaceutical manufacturer seeking to operate within or export to the United States. At the heart of these regulations are...

US FDA Inspection Types: Pre-Approval, Surveillance, and For-Cause

digi — Sun, 01 Jun 2025 10:07:47 +0000

US FDA Inspection Types: Pre-Approval, Surveillance, and For-Cause US FDA Inspection Types Explained: Pre-Approval, Surveillance, and For-Cause The United States Food and Drug Administration (US FDA) conducts a range of inspections to assess GMP compliance and protect public health. These inspections vary based on purpose, timing, and scope. For pharmaceutical manufacturers operating domestically or exporting...

FDA Form 483: Understanding and Responding Effectively

digi — Sun, 01 Jun 2025 14:45:40 +0000

FDA Form 483: Understanding and Responding Effectively FDA Form 483: How to Interpret and Respond to Inspection Observations Effectively When the US FDA concludes a GMP inspection and identifies significant issues, it issues a Form 483. For pharmaceutical manufacturers, this document signals potential noncompliance with 21 CFR Parts 210 and 211. An effective and timely...

US FDA EIR (Establishment Inspection Report) Explained

digi — Sun, 01 Jun 2025 20:47:12 +0000

US FDA EIR (Establishment Inspection Report) Explained US FDA Establishment Inspection Report (EIR): Structure, Significance, and Interpretation Following the completion of a GMP inspection by the United States Food and Drug Administration (US FDA), manufacturers receive an official document known as the Establishment Inspection Report (EIR). This document summarizes the FDA investigator’s findings and conclusions...

Preparing for a US FDA Foreign Facility Inspection

digi — Mon, 02 Jun 2025 03:49:35 +0000

Preparing for a US FDA Foreign Facility Inspection How to Prepare for a US FDA Inspection at Foreign Pharmaceutical Facilities Pharmaceutical manufacturers outside the United States supplying to the US market must comply with stringent GMP regulations under 21 CFR Parts 210 and 211. As part of this oversight, the US Food and Drug Administration...

Data Integrity Focus in FDA Inspections

digi — Mon, 02 Jun 2025 09:01:45 +0000

Data Integrity Focus in FDA Inspections Data Integrity in FDA Inspections: A Critical Focus Area for GMP Compliance In recent years, data integrity has emerged as one of the most scrutinized areas during US FDA inspections. With the increasing reliance on electronic systems, the agency has intensified its efforts to ensure that all data—whether paper-based...

FDA’s Risk-Based Site Selection Model

digi — Mon, 02 Jun 2025 15:34:14 +0000

FDA’s Risk-Based Site Selection Model Understanding the FDA’s Risk-Based Site Selection Model for GMP Inspections The US Food and Drug Administration (FDA) employs a risk-based site selection model to determine which domestic and foreign pharmaceutical facilities should be inspected each year. This system prioritizes inspections based on product risk, compliance history, and other strategic factors...

Common GMP Violations Noted in FDA 483s

digi — Mon, 02 Jun 2025 22:41:56 +0000

Common GMP Violations Noted in FDA 483s Common GMP Violations Identified in FDA Form 483 Observations Every US FDA inspection culminates in a detailed evaluation of GMP compliance, and when deficiencies are observed, they are formally documented on Form 483. These observations offer critical insights into systemic and operational gaps that may compromise product quality...

Role of FDA’s Office of Regulatory Affairs (ORA)

digi — Tue, 03 Jun 2025 04:53:40 +0000

Role of FDA’s Office of Regulatory Affairs (ORA) Understanding the Role of the FDA’s Office of Regulatory Affairs (ORA) in GMP Oversight The Office of Regulatory Affairs (ORA) is the field operations arm of the US Food and Drug Administration (FDA), responsible for conducting inspections, enforcing compliance, and protecting public health through regulatory oversight. In...